Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India Seeks To Revive National Vaccine Production Program

This article was originally published in PharmAsia News

Executive Summary

Indian authorities are considering a revival of the nation's vaccine-production program to make up for recent declines due to failures to meet international standards. Two Indian companies lost sanction by the World Health Organization because they failed to meet good manufacturing practices standards. But if the government is to revive vaccine production for bacillus calmetteguerin, cholera, diptheria, rabies, tetanus and typhoid, it may have to invest $5 billion in the effort. Among the suggestions is establishment of state-run manufacturing companies to produce vaccines companies complying with World Health Organization standards. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts